Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Cancer Res. 2019 Aug 15;79(19):5048–5059. doi: 10.1158/0008-5472.CAN-19-1246

Figure 4: Working model.

Figure 4:

The anti-αvβ3 antibody (LM609) engages tumor-associated macrophages to eliminate aggressive αvβ3+ cancer cells by triggering antibody-dependent cellular cytotoxicity (ADCC).